Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis
暂无分享,去创建一个
G. Guyatt | A. Agarwal | D. Zeraatkar | F. Foroutan | R. Siemieniuk | A. Merglen | P. Alexander | Yuan Zhang | H. Mir | O. Lesi | Yaping Chang | Yung Lee | R. Mirza | Jinell Mah Ming | Elliot Hepworth | E. Hepworth
[1] N. R. Olsen,et al. Arthroscopic surgery for degenerative knee arthritis and meniscal tears: a clinical practice guideline , 2018, Journal Title.
[2] N. Ford,et al. Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis , 2017, Journal of acquired immune deficiency syndromes.
[3] N. R. Olsen,et al. Arthroscopic surgery for degenerative knee arthritis and meniscal tears: a clinical practice guideline , 2017, British medical journal.
[4] C. Pan,et al. Lamivudine therapy during the second vs the third trimester for preventing transmission of chronic hepatitis B , 2017, Journal of viral hepatitis.
[5] Thomas Agoritsas,et al. Low intensity pulsed ultrasound (LIPUS) for bone healing: a clinical practice guideline , 2017, British Medical Journal.
[6] Linhong Wang,et al. Hepatitis B Virus (HBV) Load Response to 2 Antiviral Regimens, Tenofovir/Lamivudine and Lamivudine, in HIV/ HBV-Coinfected Pregnant Women in Guangxi, China: The Tenofovir in Pregnancy (TiP) Study. , 2016, The Journal of infectious diseases.
[7] B. Chi,et al. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. , 2016, The New England journal of medicine.
[8] N. Ford,et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. , 2016, The lancet. HIV.
[9] G. Guyatt,et al. Transcatheter or surgical aortic valve replacement for patients with severe, symptomatic, aortic stenosis at low to intermediate surgical risk: a clinical practice guideline , 2016, British Medical Journal.
[10] Gordon H Guyatt,et al. Introduction to BMJ Rapid Recommendations , 2016, British Medical Journal.
[11] A. Funk,et al. Systematic review with meta‐analysis: the risk of mother‐to‐child transmission of hepatitis B virus infection in sub‐Saharan Africa , 2016, Alimentary pharmacology & therapeutics.
[12] Shuqin Zhang,et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. , 2016, The New England journal of medicine.
[13] C. Coffin,et al. Clinical course of 161 untreated and tenofovir‐treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region , 2016, Journal of viral hepatitis.
[14] B. McMahon,et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta‐analysis , 2016, Hepatology.
[15] N. Terrault,et al. AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.
[16] Steven R. Martin,et al. Hepatitis B Virus (HBV) Variants in Untreated and Tenofovir Treated Chronic Hepatitis B (CHB) Patients during Pregnancy and Post-Partum Follow-Up , 2015, PloS one.
[17] H. Lane,et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.
[18] R. Salamon,et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.
[19] Mei-Hwei Chang,et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother‐to‐infant transmission of hepatitis B virus , 2015, Hepatology.
[20] Noele P. Nelson,et al. Outcomes of Infants Born to Women Infected With Hepatitis B , 2015, Pediatrics.
[21] F. Luciani,et al. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations , 2014, Journal of viral hepatitis.
[22] Mohammad Hassan Murad,et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis , 2014, BMJ : British Medical Journal.
[23] Yong-Feng Yang,et al. Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[24] S. Locarnini,et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. , 2014, Journal of hepatology.
[25] J. Baeten,et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. , 2014, JAMA.
[26] Hua Zhang,et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice , 2014, Hepatology.
[27] C. Pan,et al. Su1007 Tenofovir or Lamivudine Use in Late Pregnancy Safely Reduces Perinatal Transmission of Hepatitis B Virus in Real-Life Practice , 2014 .
[28] D. Häussinger,et al. Value of critical flicker frequency and psychometric hepatic encephalopathy score in diagnosis of low-grade hepatic encephalopathy. , 2014, Gastroenterology.
[29] Rodney J. Knight,et al. Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants. , 2014, Journal of hepatology.
[30] C. Flateau,et al. Hepatitis B virus (HBV) status of children born to HIV/HBV co-infected women in a French hospital: a cross-sectional study , 2014, Journal of the International AIDS Society.
[31] M. Dal,et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. , 2013, World journal of gastroenterology.
[32] C. Pan,et al. Safety of Tenofovir Disoproxil Fumarate Treatment in Late Pregnancy in Highly Viremic Mothers with Chronic Hepatitis B: 530 , 2013 .
[33] S. Matsushita,et al. Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial. , 2013, Internal medicine.
[34] S. Lockman,et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. , 2012, The Journal of infectious diseases.
[35] Gordon H Guyatt,et al. Uncertainties in baseline risk estimates and confidence in treatment effects , 2012, BMJ : British Medical Journal.
[36] Katrien Fransen,et al. Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.
[37] M. Wulfsohn,et al. Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings , 2012, PLoS medicine.
[38] I. White,et al. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses , 2012, Statistics in medicine.
[39] A. Walker,et al. Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial , 2012, PLoS medicine.
[40] G. Guyatt,et al. Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. , 2012, Journal of clinical epidemiology.
[41] J. Singer,et al. A national review of vertical HIV transmission , 2012, AIDS.
[42] Z. Xiaoming. Efficacy and Safety of Lamivudine Treatment on Preventing Hepatitis B Virus Vertical Transmission in Pregnant Women , 2012 .
[43] D. Katzenstein,et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. , 2011, The Journal of infectious diseases.
[44] S. Locarnini,et al. 736 LAMIVUDINE IN LATE PREGNANCY FOR PREVENTION OF HBV TRANSMISSION: EFFECTIVENESS AND DETECTION OF ANTIVIRAL RESISTANCE , 2011 .
[45] J. Troendle,et al. Prepregnancy Risk Factors for Antepartum Stillbirth in the United States , 2010, Obstetrics and gynecology.
[46] D. Podzamczer,et al. Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study , 2010, Journal of acquired immune deficiency syndromes.
[47] Chengcheng Hu,et al. Lopinavir Tablet Pharmacokinetics With an Increased Dose During Pregnancy , 2010, Journal of acquired immune deficiency syndromes.
[48] Lynne Peeples,et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. , 2009, The New England journal of medicine.
[49] D. Fine,et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment , 2009, AIDS.
[50] Hung‐Chih Yang,et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double‐blind, placebo‐controlled study , 2009, Journal of viral hepatitis.
[51] V. Calvez,et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. , 2008, The Journal of antimicrobial chemotherapy.
[52] Lin Wang,et al. [Effect of high viral hepatitis B virus DNA loads on vertical transmission of hepatitis B virus in late-pregnant women]. , 2008, Zhonghua fu chan ke za zhi.
[53] Gordon H Guyatt,et al. GrADe : what is “ quality of evidence ” and why is it important to clinicians ? rATING quALITY of evIDeNCe AND STreNGTH of reCommeNDATIoNS , 2022 .
[54] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[55] Hu Xiao-bing. Evaluation of therapeutic effect in HBV vertical transmission by lamivudine treatment combined with active-passive immunization for pregnant women , 2007 .
[56] R. Ebrahimi,et al. Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/Ritonavir , 2006, Journal of acquired immune deficiency syndromes.
[57] Joel E Gallant,et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.
[58] A. Zaman. Preventing Mother-to-Child Transmission of HBV , 2006 .
[59] Gordon H Guyatt,et al. Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.
[60] L. Zou,et al. Interruption of HBV intrauterine transmission: a clinical study. , 2003, World journal of gastroenterology.
[61] M. Fowler,et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. , 2000, JAMA.
[62] P. Lepage,et al. Mother-to-child transmission of HIV. , 1998, Current opinion in pediatrics.
[63] C. Giaquinto,et al. Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. The Working Group on Mother-To-Child Transmission of HIV. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.